



## BERENBERG INVESTMENT REVIEW QUARTER 2 2021

### Foreword

Dear Reader/client,

Half way through 2021 and the pandemic – certainly in the UK – seems to have entered a new phase. The delta strain is causing new cases to rise considerably, but not hospitalisations. How policy makers deal with this remains to be seen, but at the moment it seems that re-opening of our economies will continue as planned.

Economic sentiment has rebounded sharply and equities have continued their long rally. Underneath the hood there have been sharp variations between the value and growth styles indicating it is not all plain sailing.

Faster economic growth expectations have brought with them increased concerns about higher inflation and tighter monetary policy. We continue to believe that such concerns should ease in time. Nonetheless as the Covid recovery matures, we need to be mindful of the risk that either growth disappoints or central banks may be pressed quickly into action.

Our growth style has held up well despite the rally in value stocks – we pick stocks which have structural growth drivers and can pass through price increases. Whilst maintaining our positive outlook, our strategists and portfolio managers are bringing some caution to portfolio positioning.

We hope you enjoy reading about this in further detail and wish you some relaxing time over the summer.

**Richard Brass**

*Head of Wealth & Asset Management, UK*

### SECTIONS

- Overview and Q2 Asset Performance
- Normality comes into view
- Inflation takes the headlines
- Portfolio review & Outlook

### *Q2 asset performance*


As vaccination programmes progressed, especially in Europe, equities experienced a strong quarter. However, unlike Q1, Q2 saw falling bond yields as inflation expectations were tempered.

On a regional basis the US outperformed as falling yields lent a support to the growth style, which is more represented in US sector composition. Europe also performed well however with the UK lagging slightly. Emerging markets lagged as the USD bounced and tighter monetary policy and increasing regulation weighed on Chinese equities.

Yield movements were hard to read. The US conventional 10 year bond yield declined from the start of the quarter as ultimately did real yields, led by falling inflation break-even rates. One way to read this is increasing confidence that central banks will not allow inflation to rise significantly on a persistent basis. As the quarter came to a close the Federal Reserve acknowledged it is considering tapering its asset purchases, which markets read as a 'hawkish surprise'. Nevertheless, real yields fell as a result. Another reading suggests a lack of confidence in the economic growth outlook.

Gilts and sterling corporate bonds were marginally positive. Gold performed well given the environment, but suffered toward the end of the quarter when the US dollar rose.

**Chart 1: Multi-asset performance (Q2 2021 and YTD)**



Source: Bloomberg Finance L.P.  
Total Return in Sterling to Close of Business 30/06/2021

### *Normality comes into view*

The continued rollout of the Covid-19 vaccines saw economies in most of the developed world begin the process of unlocking pockets of the economy that had been shut off to prevent further spread of the virus. In regions which saw rapid deployment of the vaccines, namely Israel and the UK, vaccination rates have already exceeded 60%. European Union nations, which were a significant laggard towards the end of the first quarter, have seen significant acceleration in their schemes




## BERENBERG INVESTMENT REVIEW QUARTER 2 2021

with the share of people having received their first vaccine in the area now crossing the 50% mark.

Despite more contagious variants of the virus spreading across different regions leading to a new increase in cases, nations with high vaccination rates are seeing a muted increase in hospitalisation and mortality rates. So long as this trend continues, this would allow governments to continue with their reopening plans and allow the economic recovery to continue as the world returns to normality.

Developing nations that have lagged their developed counterparts on the vaccine front have seen a particularly large spike in cases, which has put a strain on the healthcare systems in the regions given the lack of dampening effect on medical needs seen in highly vaccinated regions. India saw a large spike in cases over the second quarter, which led to the federal government taking control of the programme offering vaccinations to all adults by the end of June. Following a meeting of the G7 countries, it was announced that 1 billion vaccines would be donated to developing nations to help address the current ongoing shortfalls.

**Chart 2: Total population to receive at least one vaccine**



Source: Our World In Data      Period: 12/12/2020 – 30/06/2021

### *Inflation takes the headlines*

As economies transition to a full reopening, economic activity continues to gather pace. This has led to a significant pickup in economic growth, albeit against soft comparisons from the largely locked down world last year. However, with an abundance of stimulus coupled with the reopening of the floodgates for economic activity, concerns of the impact of the magnitude and duration of the inflation that would follow began to emerge.

In the UK, at the end of the second quarter outgoing Chief Economist of the Bank of England Andy Haldane said he sees inflation in the UK for 2021 close to 4%, which is almost 1% higher than the value that the Bank of England itself estimated earlier in the quarter. Andy Haldane however seemed to be the sole hawk at the bank, as he cast the sole vote for scaling back monetary stimulus, with the other eight members voting to maintain the £875bn bond purchasing programme. There was no disagreement on the base rate, as all members voted in favour of maintaining the rate at 0.1%.

### *Portfolio Review*

After mildly positive returns for equity focused strategies in Q1, portfolio returns in Q2 were much stronger in absolute terms. Despite the rise in bond yields and inflation expectations, even bond focused strategies in sterling made positive returns.

In relative terms we again outperformed our benchmarks – and by a healthy margin (>2%) – in equity focused mandates. Relative outperformance was assisted by a small overweight to equities and an underweight to bonds. However, the primary driver was security selection, which was positive in all equity regions. This trend was continued in June.

During the quarter we gradually reduced our overweight to equities, which remains with less conviction. This was mainly achieved through a reduction in European equities and a trimming of our position in Latin America. We also switched some of our selections by introducing Worldline and topping up Croda. This was funded through a sale of Unilever and further profit taking in ASML as well as BE Semiconductors.

### *Outlook*

Looking out to 2022 and perhaps further, the economic outlook remains strong. There is plenty of slack for the global economy to grow into and although the inflation picture has certainly changed we do not expect it to become a material problem. Central banks have a delicate balancing act between maintaining inflation fighting credibility whilst not normalising policy so fast as to derail the recovery.

In the shorter term, we are experiencing a very rapid recovery from the pandemic lockdowns, which as yet are not over. Business confidence has soared and GDP growth has come roaring back, especially in the US, but increasingly so elsewhere as well. It is increasingly likely that from hereon in, growth disappointments become more probable and that certainly the



## BERENBERG INVESTMENT REVIEW QUARTER 2 2021

pace of growth improvement must slow. Nevertheless, GDP growth will remain strong.

The strength of the recovery has reinvigorated inflation, such that investors are increasingly wary of inflation dynamics. Presently, inflation is being boosted by year-on-year effects and supply disruptions as we emerge from the pandemic. These effects should fade as we approach 2022, however this does not end the inflation debate. There is concern that inflation may prove more sticky than in the recent past, and that many of the factors which have driven inflation lower over the last few decades (such as rapidly increasing labour supply) are now beginning to reverse.

Against this backdrop, monetary policy has grown in import. In the latter part of the quarter the Federal Reserve admitted it was discussing slowing its asset purchase programme and increased its 2 year view of where interest rates might be. Paradoxically, bond yields fell as inflation expectations ebbed. The story of Q1 had been a rise in inflation expectations and real yields.

For equity investors these gyrations cause issues in style rotation. Whilst the 1Q was very supportive for cyclical value, the 2Q has proven less so and looking forward we expect this picture to remain muddled.

Although our growth style has found this environment more difficult, our focus on companies which can pass through price increases has limited the impact of changing inflation expectations. Naturally this increases our confidence in our selections which remain heavily growth and quality oriented even though our view of equities in the short term has become more tempered in view of the uncertainty the summer will bring.

### *Authors*

#### **Richard Garland, CFA**

Senior Portfolio Manager, Wealth & Asset Management UK  
[richard.garland@berenberg.com](mailto:richard.garland@berenberg.com)

#### **William Thomas**

Investment Analyst, Wealth & Asset Management UK  
[william.thomas@berenberg.com](mailto:william.thomas@berenberg.com)

#### **Rebecca Orme**

Investment Adviser, Wealth & Asset Management UK  
[rebecca.orme@berenberg.com](mailto:rebecca.orme@berenberg.com)

### *Important Information*

This document is not, nor is it intended to be, a personal recommendation, advice on investments or an offer or solicitation to buy or sell financial instruments or other investment or banking products. Nothing in this document is intended to constitute, or be relied upon as, financial, investment, legal or tax advice. You should consult your own advisers on such matters as necessary.

All reasonable care has been taken to ensure that the facts stated in this document are accurate and that any forecasts, opinions and expectations are fair and reasonable. In preparing this document we have only used information sources which we believe to be reliable. However, the information contained in this document has not been independently verified and accordingly we do not warrant or represent that it is complete or accurate. No reliance should be placed on the accuracy or completeness of the information.

Please note the stated date of preparation. The information contained in this document may become incorrect due to the passage of time and/or as a result of subsequent legal, political, economic or other changes. We do not assume responsibility to indicate or update you of such changes and/or to prepare an updated document. We do not assume liability for the realisation of any forecasts contained in this document or other statements on rates of return, capital gains or other investment performance. By accepting this document, you agree to be bound by the provisions and the limitations set out in, or imposed by, this document and to keep permanently confidential the information contained in this document or made available in connection with further enquiries to the extent such information is not made publicly available (otherwise than through a breach by you of this provision). The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and persons into whose possession it comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of laws of any such other jurisdiction.

Nothing contained in this Important Notice shall exclude or restrict any liability for which we are not permitted to exclude or restrict by the Financial Conduct Authority, under the Financial Services and Markets Act 2000, or any other applicable regulatory authority or legislation. Berenberg is deemed authorised and regulated by the Financial Conduct Authority (firm reference number 222782). The nature and



## BERENBERG INVESTMENT REVIEW QUARTER 2 2021

extent of consumer protections may differ from those for firms based in the UK. Details of the Temporary Permissions Regime, which allows EEA-based firms to operate in the UK for a limited period while seeking full authorisation, are available on the Financial Conduct Authority's website.

For the explanation of used terms please visit our online glossary at <http://www.berenberg.de/en/glossary>